Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Bone and Calcium Disorders
What treatment options are there for Fanconi syndrome-induced osteoporosis in young female patients outside of electrolyte and mineral replacement?
Related Questions
Is there any data on denosumab use beyond 10 years from the FREEDOM Extension trial, and what do we know about the risk of atypical femoral fracture and osteonecrosis of the jaw after 10 years?
How do you counsel patients on the risks and benefits of strontium supplements for osteoporosis management?
Is there a target alkaline phosphatase level for hypophosphatasia patients on asfotase alfa therapy?
Do patients with 25 OH vitamin D levels under 20 ng/ml and normal PTH levels ("relative hypoparathyroidism") still carry a risk for bone and calcium metabolism disorders such as osteomalacia?
Would you offer bisphosphonate therapy for infants with osteogenesis imperfecta type 11?
Do you recommend the use of albumin-adjusted calcium measurement formulas to accurately assess calcium levels?
Would you have concerns with continuing denosumab for much longer than the available ten year clinical safety trial data for an individual with renal insufficiency with persistent osteoporosis/history of compression fractures?
What is the optimal management of pain and loss of function due to pathologic compression fractures?
Do oral contraceptives lower bone mineral density in women with hypothalamic amenorrhea by lowering IGF-1?
Can you use bisphosphonates in a patient with osteoporosis who has had prior avascular necrosis of TMJ due to steroid use?
